ERBB2 and gastric cancer: Moreover, a significant decrease in the HER2 ratio (1.81 ± 0.57, range, 1.18-2.91) was found in the plasma of GC patients after 2 months of FOLFOX chemotherapy combined with trastuzumab (p < 0.0001).